ClinicalTrials.gg
RecruitingNCT05687084MANECUpdated May 5, 2026

Uterine Manipulator Versus no Uterine Manipulator in Endometrial Cancer Trial

An interventional study of Uterine manipulator use in Endometrial Neoplasms, sponsored by Universita di Verona. Recruiting at 3 sites in Italy. Open to female participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Universita di Verona · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,030
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 139 studies in Endometrial Neoplasms with a site in Italy — 70 open to participants now, 87 under way, 16 of them phase 3. Endometrial Neoplasms · Italy.

Planned enrollment
5th of 96
1,030 · median 290
Started
2023
with 20 others
No phase
19 of 139
10 open now
Primary completion
2031-12
later than 84 of 86 live
Registered
69th of 139
by date

Among the 139 studies in Endometrial Neoplasms with a site in Italy, this one is the 5th largest by planned enrollment of the 96 interventional ones that give a count, is one of 21 that started in 2023, is one of 19 with no phase, reaches primary completion later than 84 of the 86 other live ones, and was the 69th registered.

Endometrial Neoplasms

1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

70 of the 139 studies in Endometrial Neoplasms with a site in Italy are open now. Recruiting first, the newest first:

65 more — sign in →

All 70 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 100 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Endometrial Neoplasms with a site in Italy, or all of them as a file.
02

Study summary

Minimally invasive surgery is the recommended approach in endometrial cancer (EC) patients based on the results of two randomized controlled trials, given its advantages without compromised oncologic outcomes. The uterine manipulator is commonly used in benign and malignant pathologies to perform a laparoscopic or robotic hysterectomy. However, although regularly used, the uterine manipulator adoption in EC is a controversial technical aspect due to the raised concerns regarding the possible risk of disruption of the tumor mass, the spread of malignant cells, and seeding of the disease, particularly at the level of the vaginal cuff or spread of tumor cells, with increased risk of recurrence and death due to EC. On that basis, given that hysterectomy without a uterine manipulator is feasible, only a randomized controlled trial comparing oncologic outcomes in EC patients after use versus not use of the uterine manipulator will be able to provide high-quality evidence to answer this critical question and allow or exclude the use of a uterine manipulator during minimally invasive hysterectomy for EC.

03

Conditions studied

  • Endometrial Neoplasms

Keywords

  • Endometrial Neoplasms
  • Uterine manipulator
  • Laparoscopic hysterectomy
  • Recurrence-free survival
  • Cause-specific survival
  • Overall survival
  • Oncologic outcomes
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Endometrial Cancer of any histology (including carcinosarcoma) and grade
  • Planned surgical treatment including hysterectomy and bilateral salpingo-oophorectomy (ovarian preservation in selected patients is not an exclusion criterion)
  • Age ≥ 18 years
  • No preoperative evidence of extrauterine disease (Clinical stage IIIA, IIIB)
  • No preoperative evidence of suspicious lymph nodes (Clinical stage IIIC)
  • No preoperative evidence of distant (Clinical stage IV)
  • Approved and signed

Exclusion criteria

Exclusion Criteria:

  • therapy
  • Synchronous or previous (\< 5 years) invasive cancer, not including non-melanoma skin cancer
  • Fertility preservation
  • World Health Organization performance score > 2
  • Uterine sarcoma
  • Previous pelvic/abdominal radiotherapy, hormone therapy for cancer (\< 5 years), chemotherapy (\< 5 years), pelvic or paraaortic lymphadenectomy, or retroperitoneal surgery
  • Inadequate bone marrow function (white blood cells \<3·0×109/L, \<100×109/L)
  • Inadequate liver function ( >1.5×upper normal limit [UNL], , and alanine aminotransferase >2.5 × UNL)
  • Inadequate kidney function ( \< 60 mL per min calculated according to Cockcroft-Gault 10 or \< 50 mL per min Ethylenediaminetetraacetic acid clearance)
  • Intraoperative evidence of stage IV disease
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,030 participants (estimated)

Study arms

  • Experimental
    Total hysterectomy with a uterine manipulator

    Total hysterectomy with bilateral salpingo-oophorectomy performed with the use of a uterine manipulator during surgery.

    Device: Uterine manipulator use

  • No intervention
    Total hysterectomy without a uterine manipulator

    Total hysterectomy with bilateral salpingo-oophorectomy performed without the use of a uterine manipulator during surgery.

Interventions

  • DeviceUterine manipulator use

    The uterine manipulator will be inserted into the uterus to assist in the procedure of total hysterectomy.

06

What researchers measure

Primary outcomes

  1. Recurrence-free survival

    Any recurrence or death related to endometrial cancer (EC) or treatment

    Time frame: Each follow-up visit, up to 4 years from the day of surgery

Secondary outcomes

  1. Cause-specific survival

    Any death related to endometrial cancer (EC) or treatment

    Time frame: Each follow-up visit, up to 4 years from the day of surgery

  2. Overall survival

    Any death for any cause

    Time frame: Each follow-up visit, up to 4 years from the day of surgery

  3. Site-specific recurrence-free survival

    Any recurrence per site of first recurrence

    Time frame: Each follow-up visit, up to 4 years from the day of surgery

  4. Operative time

    Time between first incision and skin closure

    Time frame: Day of surgery

  5. Intraoperative blood loss

    Total blood aspirate during the surgical procedure

    Time frame: Day of surgery

  6. 30-day post-surgical morbidity

    Perioperative (intraoperative and postoperative) complications graded based on the Clavien-Dindo classification

    Time frame: 30 days after surgery

  7. Lymphovascular space invasion

    Presence of lymphovascular space invasion at definitive pathology

    Time frame: Day of surgery

  8. Peritoneal cytology

    Presence of positive peritoneal cytology at definitive pathology

    Time frame: Day of surgery

  9. Quality of life indexes

    The Functional Assessment of Cancer Therapy - General (FACT-G) - A 27-item questionnaire designed to measure four domains of Health-Related Quality of Life in cancer patients: Physical, social, emotional, and functional well-being. Score range 0-108. The higher the score, the better the Quality of Life.

    Time frame: Each follow-up visit, up to 4 years from the day of surgery

07

Study locations

3 of 3 sites recruiting
  • UOC Ostetricia e Ginecologia, Azienda Ospedaliera Santa Croce e Carle
    Cuneo, Italy 12100, Italy
    Recruiting
  • UOC Ostetricia e Ginecologia, Arcispedale Santa Maria Nuova
    Reggio Emilia, Italy
    Recruiting
  • AOUI Verona - University of Verona - Department of Obstetrics and Gynecology
    Verona, 37125, Italy
    Recruiting
    • Simone Garzon, MD · Contact
08

References and documents

Publications

  • Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, Ledermann J, Bosse T, Chargari C, Fagotti A, Fotopoulou C, Gonzalez Martin A, Lax S, Lorusso D, Marth C, Morice P, Nout RA, O'Donnell D, Querleu D, Raspollini MR, Sehouli J, Sturdza A, Taylor A, Westermann A, Wimberger P, Colombo N, Planchamp F, Creutzberg CL. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021 Jan;31(1):12-39. doi: 10.1136/ijgc-2020-002230. Epub 2020 Dec 18. PubMed 33397713 ↗
  • van den Haak L, Alleblas C, Nieboer TE, Rhemrev JP, Jansen FW. Efficacy and safety of uterine manipulators in laparoscopic surgery: a review. Arch Gynecol Obstet. 2015 Nov;292(5):1003-11. doi: 10.1007/s00404-015-3727-9. Epub 2015 May 13. PubMed 25967852 ↗
  • Uccella S, Cianci S, Gueli Alletti S. Uterine manipulator in endometrial cancer: we are still far from the answer. Am J Obstet Gynecol. 2021 Mar;224(3):332. doi: 10.1016/j.ajog.2020.09.049. Epub 2020 Nov 15. No abstract available. PubMed 33207238 ↗
  • Uccella S, Bonzini M, Malzoni M, Fanfani F, Palomba S, Aletti G, Corrado G, Ceccaroni M, Seracchioli R, Shakir F, Ferrero A, Berretta R, Tinelli R, Vizza E, Roviglione G, Casarella L, Volpi E, Cicinelli E, Scambia G, Ghezzi F. The effect of a uterine manipulator on the recurrence and mortality of endometrial cancer: a multi-centric study by the Italian Society of Gynecological Endoscopy. Am J Obstet Gynecol. 2017 Jun;216(6):592.e1-592.e11. doi: 10.1016/j.ajog.2017.01.027. Epub 2017 Jan 29. PubMed 28147240 ↗
  • Padilla-Iserte P, Lago V, Tauste C, Diaz-Feijoo B, Gil-Moreno A, Oliver R, Coronado P, Martin-Salamanca MB, Pantoja-Garrido M, Marcos-Sanmartin J, Gilabert-Estelles J, Lorenzo C, Cazorla E, Roldan-Rivas F, Rodriguez-Hernandez JR, Sanchez L, Muruzabal JC, Hervas D, Domingo S; Spanish Society of Gynecology and Obstetrics Spanish Investigational Network Gynecologic Oncology Group. Impact of uterine manipulator on oncological outcome in endometrial cancer surgery. Am J Obstet Gynecol. 2021 Jan;224(1):65.e1-65.e11. doi: 10.1016/j.ajog.2020.07.025. Epub 2020 Jul 18. PubMed 32693096 ↗
  • Uccella S, Puppo A, Ghezzi F, Zorzato PC, Ceccaroni M, Mandato VD, Berretta R, Camanni M, Seracchioli R, Perrone AM, Chiantera V, Vizzielli G, Sozzi G, Beretta P, Steinkasserer M, Legge F, Stevenazzi G, Candotti G, Bergamini V, Fanfani F, Garzon S. A randomized controlled trial on the oncologic outcomes of use of the intrauterine manipulator in the treatment of apparent uterine-confined endometrial carcinoma: the MANEC Trial. Int J Gynecol Cancer. 2024 Dec 2;34(12):1971-1975. doi: 10.1136/ijgc-2024-005668. PubMed 39266205 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Dec 2031, 107 months after the start.

Of 194 non-industry interventional studies with no phase under Endometrial Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 76. This study's planned 107 months is above that.

Counting every sponsor, half of 200 studies reached it within 43 months; a quarter within 19 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2022
First posted
Jan 17, 2023
StartActual
Jan 16, 2023
Primary completionEst.
Dec 31, 2031
CompletionEst.
Dec 31, 2031
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05687084
Responsible party
Stefano Uccella (Prof. Stefano Uccella, Universita di Verona) — Principal investigator
First posted
Jan 17, 2023
Start date
Jan 16, 2023
Primary completion
Dec 31, 2031 (estimated)
Completion
Dec 31, 2031 (estimated)
Last update
May 5, 2026

Study contacts

Stefano Uccella, MD, PhD
Contact
stefano.uccella@univr.it
0039 045 812 2720
Simone Garzon, MD
Contact
simone.garzon@univr.it
0039 045 812 2720
Stefano Uccella, MD, PhD
principal investigator · AOUI Verona - University of Verona
Simone Garzon, MD
principal investigator · AOUI Verona - University of Verona
Pier Carlo Zorzato, MD
principal investigator · AOUI Verona - University of Verona

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion